Pascal Viguié
Co-Founder & CEO at ByoRNA
Bordeaux, Nouvelle-Aquitaine, France
Summary
👤
Senior🎓
Top SchoolPascal Viguié is a serial entrepreneur and biotech founder with 10+ years of leadership experience who transitioned from successful tech and e‑commerce exits to pursue life-saving science. As Co‑Founder & CEO of bYoRNA, he combines an Oxford MSc in Nanotechnology for Medicine with a track record of scaling startups and investing in diverse ventures to drive disruptive, low‑cost mRNA bioproduction. He aims to make advanced therapies—most notably CAR‑T—Affordable at scale by leveraging eukaryotic cell biofactories and a founder’s appetite for high‑risk, high‑impact problems. His background includes building and exiting internet businesses, managing institutional investments, and mentoring early‑stage biotech projects, giving him a rare blend of deep technical training, commercial savvy, and patient-driven purpose. Notably, his move into biotech was motivated by a personal encounter with childhood leukemia, a catalyst that fuels his long‑term commitment to reducing treatment cost and widening access.
10 years of coding experience
22 years of employment as a software developer
MSc in Nanotechnology for Medicine and Health Care, MSc in Nanotechnology for Medicine and Health Care at University of OxfordExecutive MBA joint degree with London Business School, Executive MBA joint degree with London Business School at Columbia Business SchoolIngénieur Polytechnicien (eq. to MS) Mathematics & Physics, Ingénieur Polytechnicien (eq. to MS) Mathematics & Physics at École Polytechnique
Russian, Slovak, Spanish, English, FrenchGithub contributions (5)
v-pascal/Anaglyph3D
Mar 2016 - Dec 2016
Contributions:200 pushes, 1 branch in 8 months
STUDIO-Artaban/LeClassico
Jun 2016 - Apr 2017
Contributions:99 pushes, 1 branch in 9 months
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.